Skip to main content
SpringerLink
Log in

Ebrotidine

  • New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Summary

▴ Ebrotidine is the first of a new generation of H2 receptor antagonists with gastroprotective activity

▴ It stimulates epithelial cell proliferative activity and produces beneficial physicochemical changes in the gastric mucus that contribute to its gastroprotective action against ethanol-, aspirin- or stress-induced gastric mucosal damage

▴ The antisecretory properties of ebrotidine are similar to those of ranitidine and ≈ 10-fold greater than those of Cimetidine

▴ This drug exhibits anti-Helicobacter pylori activity that is synergistic with a number of antibacterial agents; it inhibits the urease enzyme and the proteolytic and mucolytic activities of H. pylori, and counteracts the inhibitory effects of H. pylori lipopolysaccharide

▴ Ebrotidine is as effective as ranitidine for the treatment of patients with gastric or duodenal ulcers or erosive reflux oesophagitis

▴ Ebrotidine therapy results in significantly better ulcer healing rates than ranitidine treatment in patients who smoke.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anglada L, Marquez M, Sacristan A, et al. Inhibitors of gastric acid secretion: N-sulphonyl formamidines in a series of new histamine H2-receptor antagonists. Eur J Med Chem 1988; 23: 97–100

    Article  CAS  Google Scholar 

  2. Konturek SJ, Kwiecien N, Sito E, et al. Effects of ebrotidine on aspirin-induced gastric mucosal damage and blood flow in humans. Scand J Gastroenterol 1993 Dec; 28: 1047–50

    Article  PubMed  CAS  Google Scholar 

  3. Konturek SJ, Maczka J, Kaminski K, et al. Gastroprotective and antisecretory effects of ebrotidine. Scand J Gastroenterol 1992 Jun; 27 (6): 438–42

    Article  PubMed  CAS  Google Scholar 

  4. Slomiany BL, Piotrowski J, Mojtahed H, et al. Ebrotidine effect on the proteolytic and lipolytic activities of Helicobacter-pylori. Gen Pharmacol 1992 Mar; 23 (2): 203–6

    Article  PubMed  CAS  Google Scholar 

  5. Piotrowski J, Monta M, Slomiany A, et al. Inhibition of gastric mucosal laminin receptor by Helicobacter-pylori lipopolysaccharide: effect of ebrotidine. Biochem Int 1992 Jun; 27 (1): 131–8

    PubMed  CAS  Google Scholar 

  6. Slomiany BL, Piotrowski J, Murty VLN, et al. Mechanism of ebrotidine protection against gastric mucosal injury induced by ethanol. Gen Pharmacol 1992 Jul; 23 (4): 719–27

    Article  PubMed  CAS  Google Scholar 

  7. Agut J, Sánchez JC, Sacristán A, et al. Effect of ebrotidine on 3H-tiotidine specific binding to histamine H2 receptors [abstract no. P-111]. Methods Find Exp Clin Pharmacol 1995; 17 Suppl. A: 131

    Google Scholar 

  8. Feldman M, Burton ME. Histamine2-receptor antagonists: standard therapy for acid-peptic diseases (first of two parts). N Engl J Med 1990 Dec; 323: 1672–80

    Article  PubMed  CAS  Google Scholar 

  9. Slomiany BL, Liu J, Piotrowski J, et al. Regulation of gastric mucosal calcium channel activity by an antiulcer agent, ebrotidine. J Physiol Pharmacol 1994 Mar; 45 (1): 121–31

    PubMed  Google Scholar 

  10. Slomiany BL, Piotrowski E, Piotrowski J, et al. Enhancement of gastric mucus phospholipid secretion by an antiulcer agent, ebrotidine. Gen Pharmacol 1994 Sep; 25 (5): 1033–7

    Article  PubMed  CAS  Google Scholar 

  11. Piotrowski J, Slomiany A, Slomiany BL. Ebrotidine effect on the susceptibility of H. pylori to antimicrobial agents [abstract]. Gastroenterology 1995 Apr; 108 Suppl.: A192

    Article  Google Scholar 

  12. Palacín C, Tarragó C, Ortiz JA. In vitro anti-helicobacter activity of ebrotidine [abstract no. 440]. Am J Gastroenterol 1995 Sep; 90: 1665

    Google Scholar 

  13. López-Brea M, Romero JS, Domingo D, et al. In vitro activity of ebrotidine and ranitidine against clinical isolates of H. pylori [abstract no. F3/13]. Proceedings of the 8th International Workshop on Campylobacters, Helicobacters and Related Organisms; 1995 Jul 10–13; Winchester, England

    Google Scholar 

  14. Piotrowski J, Slomiany A, Slomiany BL. Inhibition of Helicobacter pylori urease activity by ebrotidine. Biochem Mol Biol Int 1995 Oct; 37 (2): 247–53

    PubMed  CAS  Google Scholar 

  15. Slomiany BL, Piotrowski J, Murty VLN, et al. Inhibition of gastric mucosal mucin receptors by H. pylori LPS: effect of ebrotidine [abstract]. Gastroenterology 1995 Apr; 108(4) Suppl.: A222

    Google Scholar 

  16. Brzozowski T, Majka J, Konturek SJ. Gastroprotective and ulcerhealing activities of a new H2-receptor antagonist: ebrotidine. Digestion 1992 Jan; 51 (1): 27–36

    Article  PubMed  CAS  Google Scholar 

  17. Konturek SJ, Brzozowski T, Drozdowicz D, et al. Ebrotidine, a novel H2-receptor antagonist with local gastroprotective activity. Eur J Gastroenterol Hepatol 1991 Dec; 3 (12): 941–7

    Google Scholar 

  18. Slomiany BL, Piotrowsky J, Czajkowski A, et al. Gastric mucosal EGF and PDGF receptor expression with ulcer healing by ebrotidine. Am J Gastroenterol 1994 Jun; 89 (6): 894–7

    PubMed  CAS  Google Scholar 

  19. Palop D, Romero A, Villamayor F, et al. Effect of ebrotidine against gastric mucosal injury induced by ethanol in rats: comparative study with other H2 receptor antagonists [abstract]. Proceedings of the 2nd United European Gastroenterology Week; 1993 Jul 19–24; Barcelona, Spain, A–74

    Google Scholar 

  20. Piotrowski J, Czajkowski A, Yotsumoto F, et al. Effect of ebrotidine on gastric mucosal EGF and PDGF receptor expression. Biochem Mol Biol Int 1993 Aug; 30 (6): 1127–34

    PubMed  CAS  Google Scholar 

  21. Slomiany BL, Piotrowski J, Czajkowski A, et al. Gastric mucosal laminin receptor expression with ulcer healing by ebrotidine. Gen Pharmacol 1994 May; 25 (3): 451–5

    Article  PubMed  CAS  Google Scholar 

  22. Puscas I, Puscas C. The protective effect of ebrotidine (EB) as compared to ranitidine (RT) in cysteamine (CYST)-induced ulcers [abstract]. Gastroenterology 1995 Apr; 108(4) Suppl.: 198

    Google Scholar 

  23. Romero A, Gomez F, Villamayor G, et al. Effect of ebrotidine on the density of antral G-cells in the gastric mucosa in the rat. Cell Prolif 1995; 28: 393–401

    Article  PubMed  CAS  Google Scholar 

  24. Romero A, Ribes A, Grau MT, et al. Carcinogenicity study of ebrotidine in mice [abstract no. P2/04]. Pharmacol Toxicol 1993; 73 Suppl. 2: 69

    Google Scholar 

  25. Maczka M, Kwiecien N, Obtulowicz W, et al. Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans. J Physiol Pharmacol 1992 Jun; 43 (2): 139–48

    PubMed  Google Scholar 

  26. Gabryelewicz A, Konturek SJ, Butruk E, et al. Efficacy and safety of ebrotidine compared with ranitidine in patients with duodenal ulcer. Eur J Gastroenterol Hepatol 1995 Apr; 7: 361–6

    PubMed  CAS  Google Scholar 

  27. Slomiany BL, Piotrowski J, Majka J, et al. Enhancement in the protective qualities of gastric mucus by ebrotidine during duodenal ulcer healing. Gen Pharmacol 1995 Sep; 26 (5): 1039–44

    Article  PubMed  CAS  Google Scholar 

  28. Konturek SJ, Kwiecien N, Obtulowicz W, et al. Comparison of gastroprotective and inhibitory activities of ebrotidine and ranitidine in humans [abstract]. Gastroenterology 1994 Apr; 106 Suppl.: A111

    Google Scholar 

  29. Puscas I, Puscas C, Coltau M, et al. Ebrotidine (E) a competitive antagonist of H2-receptors with cytoprotective properties, also is an inhibitor of gastric mucosa (GM) carbonic anhydrase (CA) [abstract no. 1380P]. Proceedings of the World Congress of Gastroenterology; 1994 Oct 2–7; Los Angeles, California.

    Google Scholar 

  30. Albet C, Pérez JA, Márquez M, et al. Pharmacokinetics of ebrotidine [abstract no. P-106]. Methods Find Exp Clin Pharmacol 1994; 16 Suppl. 1: 124

    Google Scholar 

  31. Rozman E, Galceran MT, Anglada L, et al. Investigation of the metabolism of ebrotidine in human urine by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. Drug Metab Dispos 1995 Sep; 23 (9): 976–81

    PubMed  CAS  Google Scholar 

  32. Rozman E, Galcerán MT, Anglada L, et al. Metabolites of ebrotidine, a new H2-receptor antagonist, in human urine. J Pharm Sci 1994 Feb; 83 (2): 252–4

    Article  PubMed  CAS  Google Scholar 

  33. Gabryelewicz A, Konturek S, Marlicz K, et al. The efficacy of different doses of ebrotidine (E), a novel H2-receptor antagonist in duodenal ulcer (DU) healing [abstract no. 1154]. Gut 1994; 35 Suppl. 4: A75

    Google Scholar 

  34. Gabryelewicz A, Konturek SJ, Butruk G, et al. Comparison of the efficacy and safety of ebrotidine and ranitidine in the treatment of duodenal ulcer (DU) [abstract no. 1170]. Gut 1994; 35 Suppl. 4: A79

    Google Scholar 

  35. Tulassay Z, Döbrönte Z, Juhász L, et al. Ebrotidine vs ranitidine in the treatment of duodenal ulcer; a multicenter, randomized, controlled trial [abstract no. 554]. Am J Gastroenterol 1994 Sep; 89: 1753

    Google Scholar 

  36. Herrero E, Matov V, Krastev Z, et al. Multicenter phase III clinical trial to compare the efficacy and safety of ebrotidine vs ranitidine in the treatment of duodenal ulcer [abstract no. P-112]. Methods Find Exp Clin Pharmacol 1995; 17 Suppl. A: 139

    Google Scholar 

  37. Stachura J, Konturek SJ, Kwiecien N, et al. Ebrotidine vs ranitidine in quality healing of duodenal ulcer (DU) [abstract]. Gastroenterology 1995 Apr; 108 Suppl.: A225

    Google Scholar 

  38. Site E, Thor PJ, Maczka M, et al. Double-blind crossover study of ranitidine and ebrotidine in gastro-esophageal reflux disease. J Physiol Pharmacol 1993; 44 (3): 259–72

    Google Scholar 

  39. Gedzlizka O. Phase III clinical trial to compare the efficacy of ebrotidine 800mg and ranitidine 300mg in the treatment of benign gastric peptic ulcer. Grupo Ferrer. (data on file)

  40. Marquez M, Ugena B, Badenas JM, et al. Seguridad y tolerabilidad de un nuevo antagonista de los receptores-H2 ebrotidina (FI-3542): en voluntarios sanos [abstract no. 34-A]. Rev Farmacol Clin Exp 1993: 167 (Special Issue)

  41. Soll AH. Pathogenesis of peptic ulcer and implications for therapy. N Engl J Med 1990; 322: 909–16

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Sanjay S. Patel & Michelle I. Wilde

Authors
  1. Sanjay S. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michelle I. Wilde
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patel, S.S., Wilde, M.I. Ebrotidine. Drugs 51, 974–980 (1996). https://doi.org/10.2165/00003495-199651060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199651060-00006

Keywords

Search

Navigation